Ariad Pharmaceuticals Inc Sample Contracts

EXECUTION COPY
Loan and Security Agreement • March 22nd, 2002 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Massachusetts
COMMON STOCK
Underwriting Agreement • March 24th, 2004 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
EXHIBIT 10.14
Agreement • March 10th, 1998 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances) • California
ARIAD PHARMACEUTICALS, INC. 15,307,000 Shares of Common Stock, par value $0.001 per share Underwriting Agreement
Underwriting Agreement • January 24th, 2013 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
INDEMNITY AGREEMENT
Indemnity Agreement • September 17th, 2008 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware

THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of September 11, 2008, by and between ARIAD Gene Therapeutics, Inc., a Delaware corporation (the “Company”), and Laurie A. Allen (“Indemnitee”).

RECITALS
Loan and Security Agreement • November 14th, 2002 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Massachusetts
AND
Common Stock Purchase Agreement • July 7th, 2000 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
RODMAN & RENSHAW, INC. 1250 Broadway, 14th Floor New York, NY 10001 212-356-0500 Fax 212-760-1080
Letter Agreement • May 19th, 2003 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York

In consideration of the services rendered by Rodman under this Agreement, the Company agrees to pay Rodman a cash fee payable immediately upon the closing of any portion of any Financing equal to 5.5% of the aggregate capital raised at such closing; provided, however, that no cash fee shall be due from the Company to Rodman under the Letter Agreement between the Company and Rodman dated as of November 7, 2002, which is superseded and supplanted by this Agreement. The Company will also pay to Rodman up to an aggregate of $25,000 to reimburse Rodman for its out-of-pocket expenses related to the Financing.

COMPANY: WARRANT AGENT:
Warrant Agreement • December 8th, 1999 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances)
and
Rights Agreement • June 19th, 2000 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
LICENSE AGREEMENT
License Agreement • November 12th, 1997 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Massachusetts
EXHIBIT 10.6 THIRD AMENDED AND RESTATED TERM NOTE
Term Note • March 27th, 2008 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances)

This Note is issued pursuant to the Credit Agreement, and the holder hereof is entitled to, and shall have, all of the benefits of the Credit Agreement, and all other agreements, instruments, guarantees and other documents executed and delivered in connection therewith and herewith. All capitalized terms not defined herein but defined in the Credit Agreement shall have the meanings given to such terms in the Credit Agreement.

7,500,000 Shares ARIAD PHARMACEUTICALS, INC. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • August 5th, 2005 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York

As Representatives of the several underwriters named in Schedule 1 hereto c/o Lehman Brothers Inc. 745 Seventh Avenue New York, New York 10019